Basel, Switzerland
Basel, Switzerland

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number one in sales among the world-wide industry in 2013.Novartis manufactures such drugs as clozapine , diclofenac , carbamazepine , valsartan and imatinib mesylate . Additional agents include cyclosporin , letrozole , methylphenidate , terbinafine , and others.In 1996 Ciba-Geigy merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis. Other Ciba-Geigy and Sandoz businesses were sold off, or, like Ciba Specialty Chemicals, were spun off as independent companies. The Sandoz brand disappeared for 3 years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta in partnership with AstraZeneca, which also divested its agrochemical business.Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations the International Federation of Pharmaceutical Manufacturers and Associations , and the Pharmaceutical Research and Manufacturers of America . Wikipedia.


Time filter

Source Type

Patent
Novartis | Date: 2017-01-25

Short interfering ribonucleic acid (siRNA), said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.


The present invention relates to stable compositions comprising a sphingosine 1 phosphate (S1P) receptor modulator, suitable for use as a dosage form. The S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino- propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula Y.


Patent
Novartis | Date: 2017-01-25

S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.


A solid pharmaceutical composition suitable for oral administration, comprising:(a) a S1P receptor modulator;(b) a filler, and(c) a cyclodextrin.


The present invention describes crystalline form of 5-chloro-N-(2-isopropoxy-5-methyl-4-(piperidin-4-ylphenyl)-N-2-(isopropylsulfonyl)phenyl)-2,4-diamine. The present invention further relates to pharmaceutical compositions comprising said crystalline form, and methods of using said crystalline form and pharmaceutical composition to treat disease.


Patent
Novartis | Date: 2017-04-12

The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.


Patent
Novartis | Date: 2017-04-12

The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.


Method for washing, with a water-based system, reusable molds for making silicone hydrogel contact lenses. The water-based washing system comprises a solvo-surfactant which is an alkyl (propylene glycol)nether wherein alkyl is a linear alkyl group having 2 to 5 carbon atoms and n is the integer 1, 2 or 3. The water-based system of the invention can effectively wash away silicone-containing components and other components of a lens formulation left behind on the molding surfaces of a reusable mold, after removing a silicone hydrogel contact lens cast molded in the reusable mold.


The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.


Sellers W.R.,Novartis
Cell | Year: 2011

In the era of next-generation sequencing, there are significant challenges to harnessing cancer genome information to develop novel therapies. Key research thrusts in both academia and industry will speed this transition, and lessons learned for cancer will more broadly shape the process for genetic contributions to the therapy of disease more broadly. © 2011 Elsevier Inc.

Loading Novartis collaborators
Loading Novartis collaborators